1-15 of 15
Stefan Faderl
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Candida Vitale, Lorenzo Falchi, Elisa ten Hacken, Hui Gao, Hila Shaim, Katrien Van Roosbroeck, George Calin, Susan O'Brien, Stefan Faderl, Xuemei Wang, William G. Wierda, Katayoun Rezvani, James M. Reuben, Jan A. Burger, Michael J. Keating, Alessandra Ferrajoli
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2359–2367.
https://doi.org/10.1158/1078-0432.CCR-15-2476
Published: 12 May 2016
View article titled, Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
Open the PDF for Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

Srdan Verstovsek, Ayalew Tefferi, Jorge Cortes, Susan O'Brien, Guillermo Garcia-Manero, Animesh Pardanani, Cem Akin, Stefan Faderl, Taghi Manshouri, Deborah Thomas, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3906–3915.
https://doi.org/10.1158/1078-0432.CCR-08-0366
Published: 16 June 2008
View article titled, Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Open the PDF for Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis in another window
Journal Articles

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7817–7824.
https://doi.org/10.1158/1078-0432.CCR-05-1070
Published: 08 November 2005
View article titled, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Open the PDF for Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia in another window
Journal Articles

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Karen W.L. Yee, Anne Hagey, Srdan Verstovsek, Jorge Cortes, Guillermo Garcia-Manero, Susan M. O'Brien, Stefan Faderl, Deborah Thomas, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Maher Albitar, Evelyn McKeegan, David R. Grimm, Toby Mueller, Rhonda R. Holley-Shanks, Leonardo Sahelijo, Gary B. Gordon, Hagop M. Kantarjian, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6615–6624.
https://doi.org/10.1158/1078-0432.CCR-05-0650
Published: 15 September 2005
View article titled, Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate

Jorge Cortes, Moshe Talpaz, Susan O'Brien, Dan Jones, Rajyalakshmi Luthra, Jenny Shan, Francis Giles, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, Mary B. Rios, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3425–3432.
https://doi.org/10.1158/1078-0432.CCR-04-2139
Published: 02 May 2005
View article titled, Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Open the PDF for Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate in another window
Journal Articles

Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

Jorge Cortes, Deborah Thomas, Charles Koller, Francis Giles, Elihu Estey, Stefan Faderl, Guillermo Garcia-Manero, David McConkey, Gira Patel, Roberto Guerciolini, John Wright, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3371–3376.
https://doi.org/10.1158/1078-0432.CCR-03-0508
Published: 24 May 2004
View article titled, Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias
Open the PDF for Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias in another window
Journal Articles

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

Francis Giles, Deborah Thomas, Guillermo Garcia-Manero, Stefan Faderl, Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli, Sima Jeha, Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill, Caroline Clairmont, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 2908–2917.
https://doi.org/10.1158/1078-0432.CCR-03-0738
Published: 06 May 2004
View article titled, A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Open the PDF for A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia in another window
Journal Articles

Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls

Hagop Kantarjian, Susan O’Brien, Jorge Cortes, Francis Giles, Jianqin Shan, Mary Beth Rios, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Michael Keating, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 68–75.
https://doi.org/10.1158/1078-0432.CCR-1035-3
Published: 20 January 2004
View article titled, Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls
Open the PDF for Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls in another window
Journal Articles

Pharmacokinetics and Pharmacodynamics of Plasma Clofarabine and Cellular Clofarabine Triphosphate in Patients with Acute Leukemias

Varsha Gandhi, Hagop Kantarjian, Stefan Faderl, Peter Bonate, Min Du, Mary Ayres, Mary Beth Rios, Michael J. Keating, William Plunkett
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (17): 6335–6342.
Published: 24 December 2003
View article titled, Pharmacokinetics and Pharmacodynamics of Plasma Clofarabine and Cellular Clofarabine Triphosphate in Patients with Acute Leukemias
Open the PDF for Pharmacokinetics and Pharmacodynamics of Plasma Clofarabine and Cellular Clofarabine Triphosphate in Patients with Acute Leukemias in another window
Journal Articles

Effects of the Proteasome Inhibitor, Bortezomib, on Apoptosis in Isolated Lymphocytes Obtained from Patients with Chronic Lymphocytic Leukemia

Jessica C. Pahler, Stacey Ruiz, Irina Niemer, Leslie R. Calvert, Michael Andreeff, Michael Keating, Stefan Faderl, David J. McConkey
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (12): 4570–4577.
Published: 10 October 2003
View article titled, Effects of the Proteasome Inhibitor, Bortezomib, on Apoptosis in Isolated Lymphocytes Obtained from Patients with Chronic Lymphocytic Leukemia
Open the PDF for Effects of the Proteasome Inhibitor, Bortezomib, on Apoptosis in Isolated Lymphocytes Obtained from Patients with Chronic Lymphocytic Leukemia in another window
Journal Articles

Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia

Hagop M. Kantarjian, Moshe Talpaz, Jorge Cortes, Susan O’Brien, Stefan Faderl, Deborah Thomas, Francis Giles, Mary Beth Rios, Jianqin Shan, Ralph Arlinghaus
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 160–166.
Published: 01 January 2003
View article titled, Quantitative Polymerase Chain Reaction Monitoring of <em>BCR-ABL</em> during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia
Open the PDF for Quantitative Polymerase Chain Reaction Monitoring of <em>BCR-ABL</em> during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia in another window
Journal Articles

Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: Follow-Up Results

Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Terry L. Smith, Francis J. Giles, Stefan Faderl, Deborah A. Thomas, Guillermo Garcia-Manero, Jean-Pierre J. Issa, Michael Andreeff, Steven M. Kornblau, Charles Koller, Milosav Beran, Michael Keating, Mary Beth Rios, Jenny Shan, Debra Resta, Renaud Capdeville, Kimberly Hayes, Maher Albitar, Emil J. Freireich, Jorge E. Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2177–2187.
Published: 01 July 2002
View article titled, Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: <subtitle>Follow-Up Results</subtitle>
Open the PDF for Imatinib Mesylate for Philadelphia Chromosome-positive, Chronic-Phase Myeloid Leukemia after Failure of Interferon-α: <subtitle>Follow-Up Results</subtitle> in another window
Journal Articles

Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate

Hagop M. Kantarjian, Susan O’Brien, Jorge E. Cortes, Terry L. Smith, Mary Beth Rios, Jianqin Shan, Ying Yang, Francis J. Giles, Deborah A. Thomas, Stefan Faderl, Guillermo Garcia-Manero, Sima Jeha, William Wierda, Jean-Pierre J. Issa, Steven M. Kornblau, Michael Keating, Debra Resta, Renaud Capdeville, Moshe Talpaz
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2167–2176.
Published: 01 July 2002
View article titled, Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate
Open the PDF for Treatment of Philadelphia Chromosome-positive, Accelerated-phase Chronic Myelogenous Leukemia with Imatinib Mesylate in another window
Journal Articles

Caspase 2 and Caspase 3 as Predictors of Complete Remission and Survival in Adults with Acute Lymphoblastic Leukemia

Stefan Faderl, Peter F. Thall, Hagop M. Kantarjian, Moshe Talpaz, David Harris, Quin Van, Miloslav Beran, Steven M. Kornblau, Sherry Pierce, Zeev Estrov
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (12): 4041–4047.
Published: 01 December 1999
View article titled, Caspase 2 and Caspase 3 as Predictors of Complete Remission and Survival in Adults with Acute Lymphoblastic Leukemia
Open the PDF for Caspase 2 and Caspase 3 as Predictors of Complete Remission and Survival in Adults with Acute Lymphoblastic Leukemia in another window
Journal Articles

The Prognostic Significance of p16INK4a/p14ARF and p15INK4b Deletions in Adult Acute Lymphoblastic Leukemia

Stefan Faderl, Hagop M. Kantarjian, Taghi Manshouri, Chin-Yung Chan, Sherry Pierce, Kimberly J. Hays, Jorge Cortes, Deborah Thomas, Zeev Estrov, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (7): 1855–1861.
Published: 01 July 1999
View article titled, The Prognostic Significance of <em>p16</em><sup><em>INK4a</em></sup>/<em>p14</em><sup><em>ARF</em></sup> and <em>p15</em><sup><em>INK4b</em></sup> Deletions in Adult Acute Lymphoblastic Leukemia
Open the PDF for The Prognostic Significance of <em>p16</em><sup><em>INK4a</em></sup>/<em>p14</em><sup><em>ARF</em></sup> and <em>p15</em><sup><em>INK4b</em></sup> Deletions in Adult Acute Lymphoblastic Leukemia in another window